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ABSTRACT 
  Crohn’s disease (CD) is an idiopathic, chronic, relapsing inflammatory disorder, which is 
most commonly involved terminal ileum and colon. The incidence and prevalence of CD has 
dramatically increased during the last 50 years; however, the etiology and mechanism of this 
disorder remain unveiled. Besides genetic susceptibility, recent integrated researches 
investigated the role of environmental triggers such as microflora, measles viruses and 
mycobacteria in the pathogenesis of CD. The association between M. avium subsp 
paratuberculosis (MAP) and CD has been heightened because of clinical resemblance to Johne’s 
disease (JD), a granulomatous enteritis in ruminants caused by MAP. Isolation of MAP from 
tissue and milk samples from CD patients and from commercial pasteurized milk and dairy 
products from JD-infected animals implies a possible re-classification of CD as zoonotic disorder. 
Clinical signs and symptoms of CD are often non-specific and a challenge to distinguish 
it from other disorders. Current methods for inflammatory bowel disease diagnosis, especially 
for CD are highly invasive, distressing and expensive. In this study, the recombinant clone pB11 
containing 1.1 kb insert, identified from a MAP genomic library constructed in E. coli, expressed 
a 20 kDa (p20) antigen encoded on 549 bp partial MAP gene with an ORF cloned in frame 
within pBAD/His cloning vector. Immunoreactivity of p20 was confirmed by Immunoblot. 
Purified p20 antigen was then used in the development of an enzyme-linked immunosorbent 
ii 
 
  
 
assay (ELISA) for possible serodiagnosis of Inflammatory Bowel Disease (IBD) associated with 
MAP infection. All variables associated with ELISA test with regard to concentrations, washes 
and incubations were optimized using hyper immune rabbit t-anti-MAP polyclonal IgG 
antibodies and sera from CD and non-CD subjects. The cut-off value for positive response was 
established as 0.3 following the analysis of statistically formulated samples from normal and 
non-CD subjects. The developed ELISA test was then used to test a blindly coded 2 17 clinical 
sera. All sera samples were tested in duplicates and in both p20-coated and uncoated micro titer 
plates. Consequently, 116/134 (87%) CD sera were positive compared to 24/83 (33%) non-CD 
sera (P<0.05). Specifically anti-MAP IgG was detected in 8/22 (36%) Ulcerative colitis and 
16/61 (26%) non-IBD sera. p20-ORF encoding sequence was recloned (pB11/B6) and the 
expressed protein reactivity remained consistent. Moreover, the full length of the cloned gene 
was also identified through blast and alignment analysis and predicted to encode 346 amino acids 
with unknown function and no identity with other known proteins. The latter supports the 
clinical data, which reflect on the unique characteristics of this antigen. The result so far suggests 
that the recombinant clone and its subclone derivative may have potential role in serodiagnosis 
of CD. 
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CHAPTER ONE: INTRODUCTION AND LITERATURE REVIEW 
What is Inflammatory Bowel Disease (IBD)? 
Inflammatory bowel disease (IBD), the general term for Crohn’s disease (CD) and 
Ulcerative Colitis (UC), is a chronic, relapsing inflammatory disorder of the gastrointestinal tract. 
While both UC and CD share common clinical features, each has unique characteristics that 
partly or wholly different in the initial pathogenesis (24, 60, 74). IBD has worldwide distribution, 
but its highest prevalence occurs in the Europe and North America, about 200 to 300 per 100,000 
people and affect more than 1-2 million people in the United States (3, 24, 41). The clinical 
manifestations usually begin in the late teens to early third decade of life and accompany the 
patients throughout the life and severely impair the quality of life. It was thought that the 
combination of genetic predisposition, environmental triggers and host-environment interactions 
led to inappropriate and uncontrolled inflammation, further disrupt mucosal homeostasis and 
severe tissue damage; however, the etio-pathogenetic processes still remain unanswered so far. 
Recently, integrated researches that explore the causes and mechanisms related to the 
development of IBD might draw the better picture concerning IBDs and provide physicians more 
effective therapeutic agents to treat and monitor the prognosis of disorders or even prevent the 
occurrence of diseases. 
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 Ulcerative Colitis (UC) 
Epidemiology 
In the United States, the statistic data is conflicting. The incidence has risen to 4 to 12 per 
100,000 populations and its prevalence ranges from 35 to 50 per 100,000 populations since late 
twentieth century (3, 24). UC most commonly affects Whites, especially Caucasians and Jewish; 
the onset of disease might occur anytime of life but with the peak between the age of 20 to 25 
years (24).   
 
Clinical Manifestations 
Ulcerative Colitis (UC) affects the colon and rectum and typically limited only the 
innermost mucosa and submucosa. Unlike Crohn’s disease, UC exhibits continuous area of 
inflammation and ulcerations from the rectum and extending proximally and lacks well-formed 
granuloma (24, 41). Further, the typical clinical finding includes diffuse inflammation, goblet 
cell depletion and glandular atrophy. Patients with UC usually show bloody diarrhea, stool, fluid 
and electrolyte imbalance, weight loss, abdominal pain and fever (41). In some cases, isolated 
regenerating mucosa bulged to appear pseudopolyps (24). Depended on the affected area, the 
Crohn’s and Colitis Foundation of America (CCFA) further classifies UC as ulcerative proctitis, 
distal colitis, pancolitis and pericholangitis. The most long term complication of UC is 
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carcinoma, especially for the patients with pancolitis, in whom the risk of developing cancer is 
20 to 30 fold more than normal population (24). 
 
Etiology 
Even though the etiologic factors are still under research, most studies suggest a 
combination of environmental and genetic factors could play a role in the genesis of UC. One 
study found that smokers have a much lower risk to acquire UC in comparison with nonsmokers 
or ex-smokers groups (0.6, 4.4 and 1.0, respectively) so that stated the protective effect of 
nicotine such as increasing colonic mucus production and inhibiting Th2 response; however, the 
real mechanism of nicotine is still unknown (4, 26). In addition, psychological stress was 
proposed as a potential trigger in up to 40% UC patients (4, 28). Some data mentioned that 
experimental colitis was established when the genetic-constructed animals are exposed to 
bacteria but not in a germ-free environment and symptoms are greatly alleviated when treated 
with antibiotics. Young people who underwent appendectomy for appendicitis or mesenteric 
lymphadenitis have less chance to get UC.  Moreover, a decreased number of anaerobic bacteria 
and lactobacillus was found in patients with active disease after examination of stool and gut 
biopsy samples. The above evidence indicated the possible role of bacterial microflora in causing 
Ulcerative colitis (4, 26, 41).  
A ten-fold increased risk among first degree relatives of patients with UC and familiar 
clustering in Jews also suggested a link to genetic factors (4). Another clue implying the 
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involvement of genetic background in the pathogenesis of UC was shown in the genome 
scanning analysis that region of chromosome 3, 7, and 12 and Human Leukocyte Antigen DR 
(HLA-DR), particularly DR2, DR4 and DRw6, are highly related to disease susceptibility of UC 
patients. Positive association between clinical UC expression pattern and polymorphisms in 
intestinal mucin gene MUC3, IL-1 receptor antagonist and tumor necrosis factor alpha have been 
reported (4, 26, 66). 
Another assumption regarded UC as an autoimmune disease. Some commensal bacteria 
and their products have been proposed as autoantigens; consequently, the hosts lose their 
tolerance to commensal bacteria so that initiation of UC begins and toward dysregulated immune 
response and further tissue damage. That hypothesis might explain the phenomenon that more 
than 70 % UC patient response to perinuclear antineutrophil cytoplasmic antibodies (pANCA) (8, 
30, 41, 65, 69). Evidence that experimental colitis caused by non-steroidal anti-inflammatory 
drugs (NSAIDs), high concentration of immunoglobulins, especially IgG1, against bacteria in 
patients with UC but not in controls, and a distinctly abnormal distribution of 
glycosaminoglycans, for example, substantial loss from the subepithelial basal lamina, leading to 
the leakage of proteins and fluids and increased exposure to enteric bacteria supported the 
hypothesis of gut permeability (41). 
      
Treatment 
Administration of drugs is usually on the basis of the location and severity of the lesions 
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and clinical experience of physicians. Like CD, the strategy to combat UC is to down regulate 
hosts’ immune response; however, that also increase the possibility and susceptibility of 
opportunistic infections (38, 41, 62). Aminosalicylate, widely used to treat UC, has anti-
inflammatory effects such as inhibitory effect of lymphocytes and reduce the production of 
immunoglobulins. Budesonie, the corticosteroids similar to prednisolone, Azathioprine, the 
immunomodulators and Cyclosporin also have been proven to control diseases more efficiently 
and induce the remission in distal UC cases (28, 41). Unfortunately, some patients do not 
respond to conventional therapy because of the resistance to drugs. Several studies to date 
proved that clinical symptoms and histological lesions were greatly improved by nicotine patches 
or nicotine gum for treatment of UC based on the proposed protective effect of nicotine. Other 
than conventional therapeutics, heparin monotherapy, short chain fatty acids (SCFA) and 
Glutamine supplementation in diet and probiotic used to modulate intestinal microflora further to 
restore the homeostasis within the intestine have been demonstrated a better likelihood to 
achieve remission status than that in the placebo control group (4,41,62). 
   
Crohn’s Disease (CD) 
History 
Dr. Dalziel in 1913 first described several clinical cases with chronic intestinal enteritis 
but not tuberculosis and noticed that the remarkable similarities in the histological characteristics 
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to pseudotuberculosis, later known as paratuberculosis, in cattle (22). This low grade 
inflammtion of terminal ileum disorder was later reported by Dr. Crohn and two colleagues in 
1932. Granulomatous lesions and other clinical manifestations similar to intestinal tuberculosis 
had them suspect the role of mycobacteria; however, the failure to identify the causative agents 
in tissue specimens using Ziehl-Neelsen staining and unability to fulfill Koch’s postulates 
unfavored the establishment of a mycobacterial etiolory so that CD was considered to be 
autoimmune in origin since then. CD is also termed as Morbus crohn’s, Granulomatous enteritis, 
Regional enteritis or Terminal ileitis (24, 63). 
 
Epidemiology 
Although present throughout the world, the greatest prevalence is found in Western 
Europe and North America since 1940s and urban areas have a higher incidence of disease than 
rural populations (45, 22, and 63). According to the National Association for Colitis and Crohn’s 
Disease (NACCD), more than 500,000 people in the United States suffer from CD today and its 
annual incidence in the United States is around 2-7 per 100,000 (3, 24). The recent study of 
inflammatory bowel disease in children reported 700 new cases during the year while 300 
expected, indicating the incidence of CD is increasing. The incidence of CD rose more than 4 
folds from the 1960s to 1970s.The geographic distribution of CD most likely suggested a north-
south gradient incidence, which means Scandinavian countries have much higher risk than 
Southern Europe. However, this gradient has disappeared during the last 10 years (50, 63). An 
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epidemiological study in Olmsted County Minnesota in 1980 stated that the incidence of CD in 
urban residents was higher than that in rural residents (24). It usually strikes people in their teens 
and twenties with a minor peak in the fifties and sixties; the average age at diagnosis is 27 years 
old and more than 90% patients present symptoms before the age of 35 (24,45). Although 
mortality is approximately 6%, the life quality of patients is severely influenced. Affliction is 
approximately the same in both genders. Whites, especially those of Jewish and Scandinavian 
descent, appear to develop the disease four to five times more often than do nonwhites (24, 45).  
 
Clinical Manifestations 
This life-long, no cure illness most commonly affects the distal ileum (35%) and colons 
(45%), but may occur in any section of gastrointestinal tract from mouth to anus and perianal 
area (24). The lesions of CD have been recognized in the mouth, larynx, esophagus, stomach, 
skin, muscle, synovial tissue and bone (18, 63, 45). Patients usually have abdominal cramps, 
diarrhea, weight loss, anemia and fever. Like UC, CD patients often suffer relapse and remission 
throughout their life.  The inflammation of CD might involve a small segment of intestine 
initially and then extend and progress extensively from mucosa to serosa. The lesions usually 
present lymphoid aggregation such as mononuclear inflammatory cells, macrophages and 
lymphocytes (60,68, 45). Like Tuberculosis, marcophages often fuse together to become giant 
cells and leads to the formation of granuloma, the hallmark of the microscopic finding in biopsy 
specimens in one-third Crohn’s patients (37). Moreover, 30% of clinical cases demonstrated 
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transmural inflammation into surrounding tissue or organs, known as a fistula, and further cause 
abscess (16, 63, 68). Because of attempts to self-repair under chronic intestinal inflammation, the 
muscle layer becomes hypertrophied and fibrosis which narrows the lumen and further leads to 
intestinal obstruction, the severe complication of CD (60, 45). 
 
Etiology 
The etiopathogenesis of CD probably involves an interaction of genetic and 
environmental triggers, but the true mechanism responsible for initiating the inflammation and 
tissue destruction remain elusive and controversial (74). Among the proposed risk factors, the 
genetic predisposition is the most dominant. 10 to 15% of patients with CD have a family history; 
higher incidence risk exists among Jews and Scandinavians and the concordance rate for 
monozygotic twins is about 44 to 53%, indicating the familial aggregation pattern of this 
disorder (74, 81). Recent genome wide screening studies suggest relevant susceptibility loci on 
chromosomes 1, 3,4,6,12,14 and 16. The linkage between CD and a pericentromeric region on 
chromosome 16q12 encoding NOD2 protein has been first identified (13, 28, 47, 74, 75). Dr. 
Girardin et al stated NOD2 (CAR15) basically expressed on monocytes is a general intracellular 
cytosolic sensor of peptidoglycan through muramyl dipeptide (MDP) detection. NOD2 
molecules can not only activate nuclear factor kB signaling pathway, the key transcription factor 
involved in initiation of inflammatory response, but also function as an antibacterial factor, 
enabling the direct killing of intracellular pathogen such as S. typhimurium (9, 19, 34, 35, 77). 
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Multiple mutations accounting for 15 to 22% of CD patients seem to alter proinflammatory 
pathway and further result in a general upregulation and production of inflammation cytokines 
which in turn cause severe tissue damage in the gut (9, 28, 59, 66, 76, 71). 
Another etiology theory proposed by Dr. Fellermann recently was that the hosts with IBD 
might be more likely to contract an intestinal infection because of a defective innate defense 
system. They found that the inflamed mucosa specimens from CD and UC patients exhibited a 
low level of defensins expression (HBD-1 and HBD-2), implying a defective antimicrobial 
barrier and in turn suggesting a defensin deficiency may play a pivotal role in the pathogenesis of 
Crohn’s disease (78,27). Since NOD2 variants only account for less than 30% of CD patients, 
other candidate susceptibility genes or environmental triggers such as viruses (especially measles 
virus and enterovirus), fungi and microorganisms possible contributed to CD have been widely 
proposed and discussed since 1932. However, no single specific causative agents have 
convincingly proved to be critical for CD (4, 13, 66, 74). Like UC, altered intestinal permeability 
contributes to CD pathogenesis has also been proposed (2, 28). However, whether increased 
intestinal permeability is the primary factor or a secondary event still needs to be investigated (2). 
Because the clinical similarities between Johne’s disease, chronic enteritis in cattle and 
ruminants recognized in 1895 by Johne and Frothingham and caused by Mycobacterium avium 
subsp. paratuberculosis and the resemblance to the appearance observed in leprosy (tuberculoid 
and lepromatous forms) and tuberculosis, CD was suspected and questioned as an infectious 
origination, especially a mycobacterial infection (28, 67,74). The failure of identifying the 
bacillus by conventional acid-fast stain caused this theory to fall into disfavor. However, when 
Van Patter isolated acid-fast organisms from biopsy specimen of three CD patients after up to 8 
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months incubation, more researchers paid more attention and investigated the possible MAP 
involvement since then. In 1984, Chiodini et al. isolated two strains of a MAP like organism 
from 11 patients with CD, not from 3 with UC or 3 with other bowel disease, which suggest 
mycobacteria indeed might be one of causes of CD (18, 29). The same group later reported the 
putative agents in their primary isolates occurred in a cell wall deficient form (spheroplast, the 
non acid fast coccobacillary forms) could transform into typical MAP like organisms after 
couples of month’s incubation (17,22,25,80). By using insertion sequence IS900, the 1.4 Kb 
unique DNA sequence of MAP discovered in 1989 encoding a 43 kDa DNA binding protein 
believed as a transposase, the spheroplast form and acid fast bacilli were proved in fact two 
different forms of MAP (15, 40). Other studies also achieved similar result by molecular typing 
(RFLP) of 5s ribosomal ribonucleic acid genes. MAP was truly identified as a human pathogen 
since the specimen from cervical lymph nodes of a 7-year- old boy with Scrofula was detected 
IS900 positive and the boy was diagnosed as Crohn’s disease after fiver years (25, 43).  
MAP was originally identified as the cause of a chronic inflammatory condition in a 
German cow. The link between these bacillus organisms and Johne’s disease of ruminants was 
later proved and has fulfilled the Koch’s postulates (40). Herd prevalence of bovine 
paratuberculosis in the countries of Europe and in the United States was estimated from 7 to 55% 
and 21 to 54%, respectively (42, 53). Poor productivity of infected animals with Johne’s disease 
cause at least an estimated loss of 1.5 billion to the agriculture and dairy industries in the United 
States alone every year. MAP is a non-spore forming, non-motile, acid fast bacillus and obligate 
intracellular pathogen. Also, it has a very complex cell wall, relatively impermeable and rich in 
lipids (15). While compared with other mycobacteria, MAP seems to be the most resistant; it can 
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persist in the environment for a long time (survive in the faeces between 152 and 246 days, and 
usually more than one year on pastures). Moreover, it exhibited more thermoresistnat and 
cholorination than M. avium, which confers the capacity of survival throughout the standard 
pasteurization process (72∘ C for 15 second) and domestic water supplies. The data reported by 
Dr. Collins et al appeared consistent with the relationship between growth rate and chlorine 
resistance (31, 36, 53 ). Several extensive surveys performed in England and Wales from 1990 to 
1994 and Dallas, Texas found that up to 7% of retail tank milk was tested positive for MAP by 
IS900 and the viable MAP could also be recovered after 4 to 12 weeks incubation, which 
indicated the possible transmission routes between human and animals by the consumption of 
diary products, meat and water (15, 22, 44). Sigurdarodottir and his colleague demonstrated and 
observed the uptake of this pathogen into the intestinal mucosa through specialized cells, called 
M cells by transmission electron microscopy. The translocated MAP later was taken by 
epitheloid macrophage in the GALT that presented the antigens to T cells and further elicit TH1 
response in which interferon gamma, interleukin 2 and tumor necrosis factor alpha were 
produced. The ability of MAP to induce the production of IL-10 suppresses macrophage 
activation and subsequent intracellular killing ability (74, 53). 
Dr. Bernstein’s group in Manitoba, Canada performed a series of population based 
studies from the mucosal specimen including CD and controls using PCR to detect MAP unique 
DNA sequence (IS900), reported 1 of UC, none of CD and 9 of 19 healthy controls detected 
positive, then stated no association between the MAP and CD (11,44); however, the hypothesis 
that the emerging infection with MAP that is initially dominated among domesticated ruminants 
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and now is crossing the species barrier, possibly even humans, thus causing subsequent infection 
and perhaps disease is gradually being supported and considered recently. MAP could be grown 
in a conventional culture from about 5 % of patients with CD but not from normal people. 
Application of IS900 polymerase chain reaction to long term culture raised the positive result to 
65% (18, 44). Furthermore, the recent studies by Dr. Naser showed MAP was detected in 86% of 
surgically resected biopsy specimen and founded in the centrifugal pellets of breast milk from 
two mothers with CD but not in the other 5 normal women. The presence of MAP in the fresh 
mucosal biopsy specimens from individuals with CD was further detected and verified by Dr. 
Hermon-Taylor group. In their studies, MAP appeared in 92% of CD patients versus 26% non-
IBD controls by nested IS900 PCR methodologies (14). Several serological tests corroborated 
PCR and culture findings. A MAP-specific humoral response such as anti-a 362 recombinant 
polypeptide IgG, anti-HupB IgA, anti-AhpC and anti-AhpD antibodies was detected significantly 
higher in CD patients than healthy controls. Two putative recombinant clones encoding MAP-
specific antigens p35 and p36 and their seroreactivities were identified and evaluated by Naser et 
al. (77% CD patient sera reacted with both antigens compared to 0% from normal controls) 
(15,25,57,79). Combined the data from the cultivation, PCR and immunoassay, the detection of 
MAP in individuals with CD is significant and indicated its possible role in disease causation. 
 
Diagnosis 
The diagnosis of Crohn’s disease now is based on a combination of clinical, radiographic, 
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endoscopic and patho-histological findings (60). Barium contrast X-rays can reveal not only the 
characteristic features such as fistula, strictures, ulceration and pseudopolyposis but also the 
extent of involvement, which in turn help physicians make accurate diagnosis and therapeutic 
decisions (45,63). Recently, endoscopy such as flexible sigmoidoscopy, colonoscopy and 
wireless capsule-like endoscopy become a more and more popular routine diagnostic tool in the 
initial evaluation of inflammatory bowel disease because not only providing the doctors the 
direct visualization through the lesions but also enabling to collect biopsy samples for 
histopathogenic evaluation. Most characteristic findings in Crohn’s disease included focal edema 
and scattered small red spots, discontinuous aphthous ulcers, strictures and cobblestoning 
appearance, the most typical features and hallmarks of CD. Transmural inflammation, 
hypertrophy and noncaseating epithelioid granulomas are reported being seen in more than 50% 
in the resected biopsy specimen and are the most important histologic features in diagnosis (60, 
63).  
Nonetheless, several drawbacks and complications might discount the application of both 
barium contrast radiography and endoscopy. Patients need to drink barium contrast, a chalky 
white material that coats on the lining of intestine, before the administration of radiography, but 
some patients might experience nausea or headache and might even be allergic to this chalky 
white medium. Anaphylactic shock and cardiac arrest have been reported so far (83). Patients 
with severe colitis should not undergo a barium enema because of the increased risk of toxic 
megacolon and perforation. In spite of the advantages of endoscopy, the requirement for an 
unpleasant bowel preparation such as sedation prior to administration, the skilled technique 
required,  the high cost, time consuming, highly invasive and discomfort would limited the 
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indications (45,60, 63). In addition, the fact that both Crohn’s disease and Ulcerative colitis share 
many overlapping clinical manifestations would give the physicians a hard time doing 
differential diagnosis and might sometimes lead to misdiagnosis or misinterpretations (60). 
Therefore, the need for developing a useful, faster, noninvasive and less laborious and expensive 
serologic assay will be beneficial in the diagnosis and differentiation of IBD, predicting the 
prognosis during treatment and serving as a screening tool for disease prevention and control.  
Several serologic tests in patients with IBD which detect the presence of antibodies 
against self or non-self proteins have been documented (56). Among serological markers, 
perinuclear antineutrophil cytoplasmic antibodies (pANCA) and anti Saccharomyces cerevisiae 
antibodies (ASCA) were extensively studied (72, 56, 30, 64, 69). Whereas pANCAs are common 
in UC (50 to 70%) but seldom found in CD (only 5-10%) compared to healthy controls (3-4%), 
ASCA IgG and IgA have been found in up to 80% of CD patients but in less than 10% UC 
patients (7, 39, 23, 56, 58, 68). Despite the high diagnostic specificity of both markers, the 
sensitivity of both markers was less than 50% which weakens their usage and application as 
diagnostic tools (51). Anti-OmpC IgA that against outer membrane porin from E.coli has been 
reported and seen in 55% of CD patients. Due to the increasing evidence showing CD might 
have an infectious cause, especially MAP, several MAP antigens as potential immunogenic 
markers were evaluated and studied recently (5, 6, 40, 51, 55). Antigen 85 complexes have been 
proposed because of high specificity and sufficient sensitivity and appearance in the earliest 
stages of infection, but its wide distribution among mycobacteria such as BCG, and tuberculosis 
restricted its use because of low specificity (53). One study conducted by Dr. Waters group 
showed early induction of humoral and cellular immune response after intratonsillar crypts 
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induction of MAP in the neonatal calves. Utilizing a lipoarabinomannan (LAM) based enzyme 
linked immunosorbent assay (ELISA), specific serum immunoglobulins were detected as early as 
134 days postchallenge, much earlier than cellular responses (194 days postchallenge) and two 
immunodominant antigens (50 and 60 kDa) were detected in the immunoblot within two weeks 
after pathogen challenge, implying the potential way to early diagnose MAP infections (82).  
Nevertheless, Kabayashi group reported no seroactivity difference between CD and 
controls by using LAM and protoplasmic antigens in ELISA. Cho et al addressed that increased 
reactivity of CD patients versus controls was not observed after examining seroreactivity to 
common mycobacterial antigens and a species-specific glycopeptidolipid (18, 44). Moreover, 
another population based seroprevalence of MAP in patients with CD and UC done by Dr. 
Bernstein et al showed no correlation between MAP and CD by using human adapted 
commercial ELISA kit originally designed for bovine paratuberculosis (10). In fact, the reason 
that most normal individuals have similar serological response as CD in these assay might be 
contributed to the common antigens, usually cell wall components such as LAM, have been 
proved the existence among all families including streptomycetaceae, Actinomycetaeae and 
mycobacteriaceae, therefore the unpurified antigens like sonicated whole cells would appear an 
indistinguishing range of reactivity among normal and disease populations. In addition, the hosts 
infected with cell deficient form of MAP would show little reactivity against these cruded cell 
wall extract and LAM antigens (20, 25, 40, 53, 82). Developing suitable serological markers 
with improved and defined specificity and sensitivity would be necessary to yield better 
diagnosis, thus confirm the etiopathogenesis on at least some subsets of CD. 
 
15 
 
  
 
Treatment 
About 40 to 60% of CD patients need surgery during the first 10 years of the onset of 
symptoms. Unfortunately, 50-60% of patients undergoing the surgery develop recurrent disease 
within 10 years (45, 63). Because of unclarifying the causative agents on CD, the goal of 
treatment plans primarily aims to suppress the immune system, relieve the clinical signs and 
symptoms and nutritional supplementation. The success of methotrexate with anti-inflammatory 
effect and Cyclosporine / Azathioprime with inhibitory effect on T cell proliferation in the 
treatment of inflammatory bowel disease have been reported and adapted as conventional 
therapeutic agents (38,62). Although corticosteroids are as effective as Methotrexate and other 
antibiotics, the safety profile, such as intolerable side effects and dependency in one-third of 
patients, narrowed their administration (4, 28). Recent studies show that the combination of anti-
mycobacterial drugs like Rifabutin and Clarithromycin that concentrated within macrophages 
can achieve marked clinical improvement within 6 to 8 weeks and maintain long-term remission, 
which also support a causable role for MAP in CD (22, 28). 
Current insights of molecular mechanisms underlying IBD have led researchers to 
develop the novel therapeutic approaches and strategies like manipulation of immuno-
inflammatory factors such as TNF blockers and anti-leukocyte adhesion molecules and gene 
therapy (70, 4). Moreover, the efficacy of nicotine believed to affect the mucin production and 
immune defense was understudied. The improvement of symptoms and endoscopic appearance 
by transdermal nicotine patches suggested its potential use as an adjunctive drug to conventional 
therapy (4, 38). 
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 Rationale for the Study 
Clinical signs and symptoms of CD are often non-specific and a challenge to distinguish 
it from other disorders. Currently, the diagnosis is based on a combination of clinical, 
radiographic, endoscopic and patho-histological findings. However, 10 to 15% of patients were 
diagnosed as indeterminate form and 2-4% patients those who diagnosed as UC and received UC 
treatment are finally determined to have CD in spite of careful evaluation. To date endoscopy 
and Barium X-ray become routine diagnostic tools, but they are highly discomfort, invasive, 
expensive, and time-consuming. Several candidates have been tested for the patients with IBD 
such as pANCA, ASCA, and lactoferrin detection kit, but the specificity and sensitivity of theses 
tools usually mark down their clinical application. Therefore, the development of a specific 
serological marker, which could accurately distinguish CD from others, would be required and 
beneficial for different clinical diagnosis. The application of such serologic tests on patients with 
IBD or non-IBD will provide significant impact toward the association of MAP with CD 
pathogenesis. Ultimately it would facilitate the identification of IBD subpopulation with MAP 
involvement, which will have impact on the choice of treatment and disease prognosis. 
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CHAPTER TWO: METHODOLOGY 
Bacterial Strain and Growth Condition 
E. coli strain TOP10 purchased from Invitrogen (Invitrogen Corp., Carlsbad, CA) and its 
recombinants were grown in Laura Britani (LB) broth media (1% w/v tryptone, 0.5% w/v yeast 
extract and 1% w/v NaCl) supplemented with ampicillin at a final concentration of 50 ug/ml. The 
2 ml starting cultures were incubated at 37 0C with agitation at 175 rpm for 16 hours until OD600 
achieves 1.2 to 1.5. The overnight culture was further transferred and grown in the large volume 
of LB broth in the similar condition. 
 
Cell Harvest 
Following incubation, cultures were transferred to 50-mL centrifuge tubes followed by 
centrifugation at 4,000 rpm and 4 0C for 15 minutes. After it was washed twice with 10 ml sterile 
Millipore water and similar centrifugation, cell pellets were used immediately for plasmid DNA 
extraction or protein analysis.  Otherwise, they were stored at – 20 0C until use. 
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Plasmid DNA Extraction and Restriction Digestion Analysis 
Extraction of plasmid DNA from E. coli and its recombinants was prepared by Qiagen 
(Qiagen Inc., Chatsworth, CA) as described by the manufacturer. The extracted plasmid DNA 
was further digested with restriction endonuclease at 37 0C for at least two hours.  
 
Agarose Gel Electrophoresis 
A 1% agarose gel was prepared by mixing 0.75g of agarose (Fisher Scientific, NJ) in 75 
ml of 0.5X Tris-Borate (TBE).  The mixture was heated in the microwave with occasional 
shaking until agarose was fully dissolved.  The flask containing the melted agarose was 
incubated in a 56 0C water bath for 15 min. 2ul Ethidium bromide (BioRad, Hercules,CA) was 
added into the melted agarose and then poured into a casting tray with variable combs.  The gel 
was allowed to polymerize at room temperature for 1 hr before use.  The gel was then transferred 
to a horizontal electrophoresis apparatus (Bio-Rad) and run at room temperature for 5 min at 95 
V.  A mixture consisting of sample and loading Dye (30% Glycerol in distilled water, 0.25% 
Bromophenol Blue, and 0.25% Xylene cyanol) with a 6 to 1 ratio was loaded into each well. The 
molecular weight standards, Lambda DNA/ Hind III (Promega, Madison, WI) and Low DNA 
mass standard (Invitrogen Corp. Carlsbad, CA), were also loaded accordingly.  Electrophoresis 
was resumed at the same conditions for 30 min. The gel was analyzed on a ultraviolet (UV) light 
box at 365 nm wavelength.  A photograph of each gel was then taken for documentation. 
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 Protein Extraction Preparation 
To optimize overexpression of recombinant protein, the recombinant colony was 
inoculated and grown in Laura Britani (LB) broth media containing 50 ug/ml ampicillin at 37 0C 
with agitation at 175 rpm until OD600 equals 1.5. The 100ul overnight culture were then 
transferred to each 10ml LB broth and grown in the same condition until OD600 was 0.5.  A serial 
dilution of L-arabinose (Becton Dickinson, Sparks, MD) at a final concentration from 0.0002% 
to 2% was added into each 10 ml culture and 1ml sample was taken every two hours from each 
tube. The aliquot of cells from each tube was centrifuged at 12,000rpm for 2 minutes and kept 
frozen at -200C for further analysis. 
For each positive transformant colony expressing a recombinant protein, a volume of 2 
ml of LB containing 50 ug/ml ampicillin was inoculated with a single colony followed by 
incubation at 370C and agitation at 175 rpm to an OD600 = 1.2.  Following overnight incubation, 
a volume of 16 ml LB containing 50ug/ml ampicillin was inoculated with 1ml of the overnight 
culture and grown overnight.  On the third day, the cultures were further transferred to 400 ml 
LB and grown at 370C with shaking to OD600 = 0.5 (mid-log phase). L-Arabinose at final 
concentration 2% (w/v) was added and the tubes were incubated for 4 more hours at 370C with 
shaking. After the aliquot of the cells (100ml each) was pelleted down at 4000 rpm, 40C for 15 
minutes, each pellet was then washed twice with 10 ml sterile Millipore water and similar 
centrifuge and stored at -200C.  
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 Purification of Recombinant Proteins 
6x His-tagged recombinant proteins were purified by immobilized metal ion absorption 
chromatography (IMAC). One pellet (from 100 ml culture) was resuspended in 4 ml 
resuspension buffer containing 50 mM Tris, pH8.0, 300 mM NaCl, 10mM Imidazole and 0.2% 
Triton X-100 and further sonicated.   Cell lysate was span for 10 minutes at 12,000 rpm and 
supernatant was loaded into pre-equilibrated Ni-TED silica prepacked column (Active Motif 
Corp, Carlsbad,CA). The column was washed with 3 ml Wash buffer (50mM Tris, pH8.0, 
300mM NaCl and 20mM Imidazole) 5 times and elute the recombinant protein out with 1ml 
Elution buffer(50mM Tris, pH8.0, 300mM NaCl and 250mM Imidazole) three times.  The flow 
chart of purification was shown in Figure 1. 
 
SDS-Polyacrylamide Electrophoresis and Silver Staining 
SDS-PAGE was done using the Mini-protein II Dual slab cell unit according to 
manufacturer’s instruction. Discontiunous polyacrylamide gels (12% w/v separating and 4 % w/v 
stacking gels) were prepared. Following electrophoresis, gels can be silver stained to visualize 
bands. Gels were first fixed at fixative solution I containing 40 %( v/v) methanol and 10% (v/v) 
acetic acid for 30 min at room temperature followed by two 15 min incubations with fixative 
solution II which consists of 10% (v/v) ethanol and 5% (v/v) acetic acid. Gels then were 
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incubated with 50 ml of 10% (v/v) potassium dichromate and nitric acid containing oxidizer 
(BioRad) for 2 min and rinsed with Millipore water until clear. After incubated with 50 ml of 
10% (v/v) silver nitrate containing silver reagent for at least 30 min and rinsed twice with 
Millipore water, gels were developed with 100ml of 3.2% (w/v) Silver stain developer including 
carbonate and paraformaldehyde. Until the bands reached the desired density in relation to 
background, the reaction was stopped by 5% acetic acid.  
 
Immunoblotting 
Each cell pellet resuspended in 25 ul of sterile deionized water and 75 ul sample buffer in 
a pilot protein overexpression study or a mixture of 10ul each fraction during IMAC purification 
and 15 ul sample buffer were solubilized by boiling for 15 minutes and fractionated by 12% 
SDS-PAGE, which were followed by transferred onto nitrocellulose membrane (Bio-Rad 
transblot medium) using a Bio-Rad Trans blot mini electrophoretic chamber (120 V, 80 A for 1 
hour).  A prestained protein molecular weight standard (Bio-Rad) was included in each SDS-
PAGE gel.  Immunoblot filters containing fractionated proteins from recombinant E. coli were 
blocked with 1% BSA in tris-phosphate buffered saline (PBST) buffer at either 4 0C overnight or 
room temperature for at least 3 hours. The membrane was washed with PBST twice for 5 
minutes each and then incubated with anti-Xpress™ monoclonal antibody (1:4000) at 40C 
overnight with gentle agitation. The membrane was again washed twice with PBST and 
incubated with 1:4000 diluted Goat anti-mouse IgG-peroxidase conjugates. After similar washes 
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were performed, signal on the membrane can be visualized by adding opti-4CN diluent solution 
substrate (Biorad). Following color development, filters were washed in distilled water and air-
dried. 
 
Nucleotide Sequence Analysis 
For sequencing, the pBAD forward and reverse primers provided by Invitrogen were 
used to sequence the entire nucleotide sequence of the insert.  After plasmid extraction, samples 
were sent to the DNA Sequencing Core at University of Central Florida for automated 
fluorescent DNA sequencing.  
DNA sequence analysis was done by using a search and retrieval system called Entrez.  
This system integrates information from databases at the National Center for Biotechnology 
Information (NCBI, http:// www.ncbi.nlm.nih.gov/). The nucleic acid and predicted amino acid 
sequences for the recombinant clones were further compared with those in the NIH genetic 
sequence database (GenBank). 
 
 
 
 
 
 
23 
 
  
 
  
 
 
 
 
 
 
Figure 1: Flow Chart of Purification Process of 6x His-tagged Proteins Using the Ni-TED 
Protein Purification System. 
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 Phospate buffer, pH 8 
Tris buffer, pH 8 
300 mM NaCl 
10 mM imidazole 
Bind 
pH 6.3 
Ni-TED Silica Column 
20 mM imidazole 
pH 5.9 or pH 4.5 
Pure 6xHis-tagged protein 
250 mM imidazole 
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Construction of pB11 Subclones 
Genomic DNA Extraction 
Genomic DNA from MAP strain Linda, other mycobacterial isolates such as M. 
tuberculosis and M. smegmatis ATCC27199 and E. coli were extracted and purified by the 
enzymatic method.  Cell pellet of 50 ml culture was suspended in 2 ml of Tris.HCl-EDTA (TE) 
buffer containing 50 mg lysozyme (Sigma, St. Louis, MI).  The mixture was incubated for 24 h 
at 37 0C with occasional shaking. A solution containing Sodium dodecyl sulfate (SDS, 3% final 
concentration) and proteinase K (3.5 mg/ml) was added and continued incubation at 55 0C for 2 
h.  The mixture was extracted with equal volume (v/v) of phenol (Sigma) by gentle mixing and 
centrifugation at 3,000 rpm and room temperature for 10 min.  The aqueous phase was extracted 
twice with equal volume of chloroform (v/v) by gentle mixing followed by centrifugation at 
3,000 rpm for 20 min.  The aqueous phase containing DNA was mixed with two volumes of cold 
100% ethanol.  The chromosomal DNA was spooled out onto a glass rod, transferred to a 1.5-ml 
eppendorf tube containing 1.0 ml of 70% ethanol. The eppendorf tube was then centrifuged at 
14,000 rpm and 4 oC for 10 min.  Each DNA extract was air dried, then reconstituted in 200 ul of 
either sterile Millipore or TE buffer (10mM Tris, 1mM EDTA , HCl) and stored at 4 oC.  
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The Cloning System 
The pBAD/His is a pUC-derived expression vector purchased from Invitrogen.  A 
diagram of these plasmid vectors was shown in Figure 2. It is designed for regulated, dose-
dependent recombinant protein expression and purification in E. coli.  The regulatory protein, 
AraC,was provided on the pBAD/His vector allowing regulation of PBAD.  In the presence of 
arabinose, expression from PBAD was turned on while the absence of arabinose produces very 
low levels of transcription from PBAD.  By varying the concentration of arabinose, protein 
expression levels could be optimized to ensure maximum expression of soluble protein.  The 
plasmid pBAD/His is a 4.1 Kb prokaryotic expression vector.  It has the following features: the 
PBAD promoter and the araC gene product for regulated expression of the gene of interest, N-
terminal polyhistidine tag for rapid purification of fusion proteins using ProBond™ resin, anti-
Xpress™ epitope for detection of fusion proteins with the Anti-Xpress™ Antibody, enterokinase 
cleavage site to facilitate removal of the fusion protein, multiple cloning site in three reading 
frames to simplify subcloning in frame with the N-terminal polyhistidine tag, and ampicillin 
resistance gene and ColE1 origin for selection and maintenance in E. coli.  
After being digested by Eco RI and HindIII restriction endonucleases, the plasmid 
pBAD/His was dephorsphorylated by Shrimp alkaline phosphatase (SAP,  Promega) for 1 h at 37 
0C to prevent self ligation.  The shrimp alkaline phosphatase was inactivated by heating for 10 
min at 70 0C. 
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 Primers Design 
Based on the nucleotide sequence published on database, sets of oligonucleotide primers 
carrying restriction recognition sites were designed and used to amplify a possible open reading 
frame as shown in Table 1.   
 
Table 1: An Overview of Primers Used in This Assay. 
Primer Sequence Target Tm (℃) Product (bp)
F 5' GTGGCGGAATTGTAATACGACTCACTAT 60.3
R 5' CGATAAGCTTGCTCACTCACCACCTA 61.9
F 5' CATTGGTACCCCTGAACATGACGCCGCA 63
R 5' CGATAAGCTTGCTCACTCACCACCTA 61.9
F 5' ATGCCATAGCATTTTTATCC 54
R 5' CGATAAGCTTGCTCACTCACCACCTA 61.9
Subclones 817
pB11 660
MAP 900
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Figure 2 : pBAD/His Cloning System. 
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 Polymerase Chain Reaction (PCR) 
The PCR reaction was performed in a total volume of 50 ul containing PCR reaction buffer, 
3M Betaine , MgSO4 solution at a final concentration of 50mM,10 mM of deoxynucleotides 
(dATP, dCTP, dGTP, dTTP); 3ul of each set of the primers; 1 unit of High Fidelity Taq DNA 
polymerase; and 1 ul volume DNA template of either MAP strain Linda or plasmid DNA 
carrying 1108bp insert. The reaction mixture was subjected to 30 cycles of amplifications 
performed in a programmable thermal controller, as follows: 5 minute denaturation at 95 0C, 
denaturation at 940C for 45 seconds , 30 second annealing at 58 0C; and 1 min primer extension 
at 72 0C. After the 30 cycles, reactions were extended for 10 min at 72 0C. 
 
Purification of Amplified DNA 
To clean up the contaminants, including primer dimmers, non-specific amplification 
products and templates, the PCR amplified DNA was purified by Wizard PCR Preps DNA 
Purification system (Promega). The PCR products were first separated by electrophoresis on 1% 
(w/v) low melting agarose gel (Fisher Scientific). The excised gel slice (around 300mg) was 
transferred to 1.5 ml microcentrifuge tube and heated at 70 0C until the agarose was completely 
melted. 1 ml resin was then mixed with melted agarose thoroughly and slowly passed through 
the minicolumn by 3-ml syringe. After washed with 2ml 80% isopropanol, DNA was eluted out 
with 50 ul sterile water at 9,600 rpm for 1min. 
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Ligation 
The dephosphorylated pBAD/His vector (50 ng) was then ligated to an EcoRI and 
HindIII PCR digest using T4 DNA ligase (Promega) following standard procedure.  Using a ratio 
of 1:3 for the vector to genomic DNA digest, the ligation mixture was incubated at 16 0C 
overnight.  As a control, a tube containing dephosphorylated pBAD/His vector only was treated 
under the same conditions. 
 
Transformation by Electroporation 
The ligated mixture of pBAD/His and digested amplified product was transformed into E. 
coli TOP10 competent cells by electroporation as described by Sambrook et al. Electroporation 
was performed using the Gene Pulser and Pulse Controller instruments from Bio-Rad (Bio-Rad 
Laboratories, Richmond, CA).  A volume of 2 ul of the ligated DNA was mixed with 50 ul of 
electrocompetent E. coli TOP10 cells.  It was placed on ice for few minutes and then the cells 
were transferred into an ice cold 0.2 cm electrode chamber (electroporation cuvette).  
Electroporation was performed at 2.5 KV and 9.6 milliseconds using the standard setting.  The 
electroporated cells were suspended in 1.0 ml of SOC medium, incubated for 1 hr at 37 0C, and 
then spread onto LB agar plates containing ampicillin (50 ug/ml).  The plates were incubated at 
37 0C for overnight. pBAD/His DNA only was transformed under the same conditions as a 
control. The colonies were further screened and verified by cell pop PCR described later. 
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 Screening the Subclones by Cell Pop PCR 
The PCR reaction was performed in a total volume of 25 ul containing PCR reaction 
buffer, 3M Betaine , MgSO4 solution at a final concentration of 50mM,10 mM of 
deoxynucleotides (dATP, dCTP, dGTP, dTTP); 1.5ul of each set of the primers; 0.5 unit of High 
Fidelity Taq DNA polymerase; the colonies were ramdonly picked from the agar plate by sterile 
toothpick and directly serve as DNA template without DNA extraction. The reaction mixture was 
subjected to 30 cycles of amplifications performed in a programmable thermal controller, as 
follows: 15 minute denaturation at 95 0C, denaturation at 940C for 45 seconds , 30 second 
annealing at 50 0C; and 1 min primer extension at 72 0C. After the 30 cycles, reactions were 
extended for 10 min at 72 0C. The amplified products are electrophorized and visualized under 
UV light as described before. 
 
Screening Subclones by Immunoblotting 
The PCR positive subclones were grown, induced with 2 % L- Arabinose and harvested 
as described before. Each cell pellet resuspended in 25 ul of sterile deionized water and 75 ul 
sample buffer were solubilized at 95∘C for 15 minutes and fractionated on 12% SDS-PAGE gel 
followed by transferred onto nitrocellulose membrane (Bio-Rad transblot medium) at 4∘C for 
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12 -16 hr with costant voltage of 40 V using a Bio-Rad Trans blot mini electrophoretic chamber.  
A prestained protein molecular weight standard (Bio-Rad) was included in each SDS-PAGE. 
Immunoblot filters containing fractionated proteins from recombinant E. coli were blocked with 
1% BSA in PBST buffer at either 4 0C overnight or room temperature for 3 hours. 
Immunodetection was performed as previous described. 
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
Preparation of Clinical Sera 
The rabbit sera were adsorbed in a mixture of non-recombinant E.coli (Invitrogen Corp., 
strain TOP10 transformed with the pcDNA II) sonicate suspended in 2 ml of PBS and a boiled 
pellet, each prepared from 100 ml of overnight LB-broth cultures containing 50 ug/ml ampicillin.  
The adsorption was at a dilution of 1:30 (v/v; serum / sonicate-pellet mixture) for 16 hours at 4 
0C.  After absorption, the mixture was centrifuged at 3,000 rpm and 4 0C for 15 min.  The 
supernatant was stored at -800C in aliquots until use. 
Sera from CD and UC patients were provided by Dr. Ira Shafran (Orlando, FL) and Dr. 
Valentine (Gainesville, FL).  1:30 sera diluted in Blotto reagent which contains 10% non-fat milk 
in PBS and Tween-20 at final concentration of 0.05% serve as primary antibodies. 
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ELISA 
96-well microtiter plates (Fisher Scientific) were coated with purified recombinant 
protein (400ng/well) at either room temperature or 4 0C. The wells were 11further blocked with 
Blotto reagent at room temperature for three hours. After three washes with Phosphate buffer 
Saline (PBS, pH7.2, Sigma), diluted sera samples, positive and negative controls were dispensed 
to duplicate microtiter well and incubated for 2.5 hour at room temperature. Unbound Serum 
components were then removed by washing the wells 5 times with PBST and 3 times with PBS. 
After removal of residual wash fluid, 100 ul of HRP conjugated anti- human IgG (1:6000) was 
added into each well and incubate at room temperature for another hour. After adequate washes 
as before, 100ul of tetramethyl benzidine substrate solution (TMB) was added to each well and 
incubated for 5 minute.  The enzymatic reaction was stopped by 100 ul of 1 M Phosphoric acid 
and OD for each well was measured at 450nm.   
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CHAPTER THREE: RESULTS 
Preparation and Confirmation of pB11 Clone 
The recombinant clone pB11 clone was constructed and identified from the genomic 
library of MAP strain Linda (ATCC 43015) using 4.1 Kb prokaryotic cloning and expression 
system (pBAD/His) two years ago in our lab, which contains pBAD promoter and araC gene for 
regulated expression of the gene, provides better screening and purification of expressed 
recombinant protein in E. coli , and includes the ampicillin resistance gene for selection and 
maintenance in E. coli.  
 
 At DNA Level 
The pB11 clone was inoculated and grown in the LB broth. After harvested at 4° C by 
3000 rpm for 15 minutes, plasmid extraction from washed cell pellet was performed using 
Qiagen midiprep kit as described by manufacturers. 
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Restriction Endonuclease Digestion 
In order to confirm the recombinant clone, extracted plasmid was further digested with 
restriction endonuclease enzyme EcoRI. Both undigested and digested products were 
electrophoresized on 1% agarose gel together with DNA size standards. One band showing 5 Kb 
in the undigested sample and two bands showing 4 and 1.1 Kb in the digested sample were 
observed as shown in Figure 3. 
 
Nucleotide Sequence Analysis of Recombinant Clone pB11 
The same DNA fragment in pB11 was purified and recloned in pcDNA II cloning vector 
while recombinant clone was constructed, designated as pB11 in pcDNAII, containing T7 and 
Sp6 primers used for nucleotide sequencing. Both clones, pB11 and pB11 in pcDNAII, were 
grown and harvested in the same condition and the plasmids were purified and sent to DNA 
sequencing lab for fluorescent automated sequencing. The nucleotide sequence from the entire 
DNA insert from T7 site to Sp6 site in pB11 in pcDNAII or from pBAD forward to pBAD 
reverse site in pB11 were shown. The 1088 base pairs had a G+C content of 71%, which is 
consistent with the high GC content of a mycobacterial genome. The nucleotide sequence as 
shown in Figure 4 was further blasted and analyzed by comparative computer analysis in the 
National Center for Biotechnology information databases (http://www.ncbi.nlm.nih.gov/). The 
sequences showed more than 98% similarity with that M. avium subsp. paratuberculosis strain 
37 
 
  
 
K10 while compared with other microbial genome. 
Using NCBI Open reading frame (ORF) finder database, an open reading frame of 549 
bp (shown in Figure 4) encoding a peptide consisting of 182 amino acids with a relative 
theoretical molecular weight of 20kDa, designated as p20, was identified. The deduced 
polypeptides did not reveal any similarity with any known mycobacterial or non-mycobacterial 
protein in public databases, indicating the unique characteristic of this recombinant protein. 
 
At Protein Level 
After confirmation of pB11 clone at DNA level, the characteristics of recombinant 
protein from pB11 such as secretory, solubility need to be recognized and identified. The 
recombinant clone containing a 1,088-bp insert was grown and harvested as described in the 
methodology section. Samples taken from the culture medium, cells, supernatant fraction and 
pellet portion from lysed cells after sonication were analyzed on immunoblot against monoclonal 
anti-XpressTM antibody following SDS-PAGE. pB11 expressed 23 kDa non-secretory and 
soluble protein, designated as p20, including 3 kDa tag protein as figure 6 shown. 
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Figure 3: Restriction Endonuclease Digestion of Recombinant Clone (pB11). Plasmid DNA from 
clone pB11 and vector pBAD/His B were extracted, digested with EcoRI and then analyzed on 
1% agarose gel.  Lanes: M: λ Hind III DNA size standards; 1: linealized DNA from pBAD/His 
B vector; 2: undigested pB11 plasmid DNA; 3: EcoRI digested pB11 plasmid DNA. 
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Figure 4: Nucleotide Sequence Analysis of the pB11 Insert. 
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1 GAATTCTCGC GACGGTGGCG ATGTCGTCGT CGGCGGTGCG CCGCGGCAGC 
51 AGCGCCAGCG TCGGCGCGTA GCCGACGGCG GGCGCCTGCC GGGGATAGCC
101 CGCGCGCAAA AACCCGACCA CGCCGCCCAC CAGCTGCCCC AGGCCCATGT
151 CTCACCTCGC TACCTCACCG CACGCCGCAC GCCGACAACG CCGTTGCACC
201 CCGAATAGCC GGACCCGATC CCCCTCCCCT CACGCGCACG GAAAGGGCCC
251 GGTCCGCCGA TCGGACCGGG CCCCTCCCCT TGGCGGGCAG CCTATTGGTT
301 CTTCTTCTGG CGCTCCTCGG CGGCCTCCGC GCCGGCCCGC GCCGACTCGG 
351 CCTCGGCTTC CTTCTTGCCC GCGTCGCGCT GGGCGTCGGC CTTGTCCTGC
401 TGGGCCTGAC CCTCTTCGGT CAGGTCGTCG CGGCCGAGGA TGGTCCCGCC
451 GACCTCCTTG GCCTTGCCCT TCACGCCCTC GACGGCGCCT TTGACCGCTT 
501 CCTGCGGCCC GCTCTGCTGG TCCCCCATGG GTTCGACCTC TCTGGTAGGT
551 GGTGAGTGAG CTTGCGCTCG ATGGCATCCA AGGCGTTCCC GCCGCGGGCG 
601 GTGTCAAACG GTTCGTCCGG TATCGCGCCC GGGATGTGCG GGCCGTCACC 
651 GCGGGCCCGG CGGCCGGCGC AGGTCACGCC GCGGACCGGC GGTCGGCGGG    
701 TTTGAACGGG CCGTTACTGG GTAGCTCCCC CGCGGCACGG AGCAGAAGGC 
751 AGGTGAGAGC ACTGACCACC ATCGCCGTGA TAGGGGCAAC CGGCACGGCC 
801 GGCTCCCGCG TCGTCGCCCG GCTGAGGCCG CGTGACGTCG CGGTGGTCGA 
851 GATCTCCCGG GCGCAGGGTG TCGACGTGTT CGACGCGCCC GGGCTCACCC 
901 GGGCGCTCGA GGGGGTCGAC GTCGTCATCG ACGTCTCCAA TCCGGTGCCG 
951 CCCGACGGGC GATCCGACAT CCGGCAGACG CTGGCCACCG CCGCCCGCAA
1001 CATCATGGGG GCGTGCGCCA CCCAGGAAGT ACAGCGCCTG GTGGTGTTGA
1051 CGATCGCCGG  CATCGAGGAC  CCGGTGTTCG ACGAATTC 1088  
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Figure 5: Possible Open Reading Frame Region of Recombinant Protein (p20). 
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Overexpression of Recombinant Protein (p20) 
The following strategy including various arabinose concentrations, the time course of 
protein expression and different culture temperature was applied to determine the best conditions 
for optimal expression of p20. pB11 was grown as methodology section described and the 
samples were analyzed by immunoblot against anti-XpressTM antibodies following SDS-PAGE. 
In the pilot expression study, the longer recombinant clone cultured and more L- arabinose added, 
the greater amount of protein was expressed; however, some extra bands (non-specific E.coli) 
were also found on the membrane in the 8 hour and overnight incubation samples as shown in 
Figure 7 . There is no different efficiency of protein expression between 25 and 37 degree during 
the fixed incubation time and L-arabinose concentration (data not shown). Combined all the 
possible key factors (incubation time, inducer concentration and temperature) in regulation of 
protein expression together, the maximum overexpression of fusion protein p20 can be gained 
while cultured at 37 degree, 2 % L- Arabinose and 4 to 6 hours incubation time after induction. 
 
Evaluation of Cell Crude Lysates of pB11 against Clinical Sera by Immunoblotting 
Previous studies published from our lab reported that different pattern while testing 
serum samples from patients with Crohn’s disease, Ulcerative Colitis, non-inflammatory bowel 
diseases (NIBD) and healthy individuals against MAP sonicate antigens or partial purified P20 
antigen. The seroreactivities of purified P20 antigen was further studied and reinvestigated. The 
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membrane containing the recombinant p20 antigen was cut into 3mm strip and incubated with 
anti-XpressTM antibody or clinical patient sera.  A clear band within the range of 23 kDa was 
detected, showing the recombinant protein p20 is CD specificity (Figure 8). 
 
Development of Enzyme-linked Immunosorbent Assay (ELISA) 
Purification and Quantification of Recombinant Protein (p20) 
The recombinant protein (p20) carries a polyhisitdine region at its N-terminus, which 
forms metal binding site to facilitate the purification process.  4 ml supernatant from cruded cell 
lysate was loaded in to pre-equilibrated pre-packed Nickel bound resin column (Ni-TED). 
Several washes and elutions were performed with an imidazole gradient under native condition 
as manufactures suggested. During the purification process, all fractions from flow through, 
washes and elutions were collected and loaded on to 12% SDS-PAGE gel and analyzed by either 
silver stain or immunoblot. Compared with cell lysate, flow through and washes, a much cleaner 
band appearing estimated 23 KDa was found in the second elution fraction and most of the bands 
presented in the cruded lysate were removed as Figure 9 shows. 
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Figure 6: Identification of Recombinant Protein (p20) from pB11. (A) Cell crude lysate from 
recombinant clone pB11 with or without L-arabinose induction were loaded on 12% SDS-PAGE 
gels, then silver stained. Lanes: M: protein size standards; 1: induced; 2: uninduced. (B) Cell 
crude lysates from recombinant clone pB11 and vector (pBAD/His B) were fractioned on 12% 
SDS-PAGE, transferred on to nitrocellulose membrane and probed with anti-XpressTM antibody. 
Lanes: M: protein size standards; 1: cell lysate from clone pB11; 2: culture medium fraction 
from pB11; 3: cell lysate from pBAD/His B vector; 4: culture medium fraction from pBAD/His 
B vector. 
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Figure 7: Optimization of Recombinant Protein (p20) Expression.  Various L-arabinose 
concentrations to use for induction and a time course study were run to determine the optimal 
expression condition. Collected samples were analyzed by immunoblotting. Lanes: M: protein 
size standards; 1: before induction; 2: 2 hours after induction; 3: 4 hours after induction; 4: 6 
hours after induction; 5: overnight induction. 
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Figure 8: Evaluation of Cell Crude Lysate of pB11 against Human Sera.  Clear cell lysate was 
fractioned on 12% SDS-PAGE gel and blotted on to nitrocellulose membrane. Immunoblot was 
cut and tested against anti-XpressTM  antibody (lane 1) and sera of normal healthy control (lane 2) 
or CD patients (lane 3). 
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In order to develop a quantitative enzyme-linked immunoabsorbent assay (ELISA), the 
amount of recombinant protein (p20) after affinity chromatography purification was measured 
and estimated by Bradford method, a dye-binding assay where a differential color change of a 
Coomassie Brilliant Blue G-250 dye occurs in response to various concentrations of protein. A 
protein standard curve using Bovine Serum Albumin was created to provide a relative 
measurement of recombinant protein concentration while measurement at 595 nm. The 
concentration of recombinant protein was calculated, about 70 ng/ul after purification (Figure 
10). The experiment was repeated using different batches and results were the similar. 
 
Seroreactivity of Purified Recombinant Protein (p20) 
Previous studies published from our lab reported that different pattern while testing 
serum samples from patients with Crohn’s disease, Ulcerative Colitis, non-inflammatory bowel 
diseases and healthy individuals against MAP sonicate antigens or partial purified P20 antigen. 
The seroreactivities of purified P20 antigen was further studied and reinvestigated. The 
membrane containing the purified recombinant p20 antigen following by SDS-PAGE was cut 
into 3mm strip and incubated with anti-XpressTM antibody or clinical patient sera. A clear band 
within the range of 23 kDa was detected in sera from CD patients but not from healthy controls, 
showing the recombinant protein p20 is CD specificity (Figure 11). 
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Figure 9: Purification of Recombinant Protein (p20) Using Immobilized Metal-Chelate Affinity 
Chromatography System (IMAC). After expression of recombinant protein (p20) was induced 
with L-Arabinose under optimal condition, cells were harvested and sonicated. Clear lysates 
were directly loaded into Ni-TED purification column. All fractions including lysates, flow 
through, washes and elutes were separated on SDS-PAGE and then analyzed by either silver 
staining (A, B) or immunoblot (C). Panel A before purification: M: protein size standards; 1.Cell 
crude lysate fraction after sonication. Panel B: Elute fractions after purification. Panel C: M: 
protein size standards;1: lysate; 2: flow through; 3.and 4: washes; 5: Elutes. 
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Figure 10: Quantification of Purified Recombinant Protein (P20). The amount of purified fusion 
protein (p20) from 100 ml culture was estimated (as star mark) using Bovine serum albumin 
(BSA) as standard curve by Bradford assay.  
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 Optimization of ELISA Condition 
To set up a reliable and durable ELISA, several parameters such as quality of 
recombinant protein (p20), blocking buffer, coating temperature and concentration of antibodies 
need to be optimized.  Amount of protein to coat the microplates has been optimized and 
determined as 400 ng per well in previous studies from Dr. Naser’s lab. The rest of parameters 
mentioned above were further investigated. 400 ng purified recombinant protein (p20) was 
coated into each well at either 4°C or room temperature(Figure 13 A) against serial dilution of 
anti-XpressTM antibody (Figure 12 B), rabbit and human sera (Figure 13) using either 1% BSA or 
Blotto as sample diluents and blocking buffer (Figure 12). No statistically significant difference 
between 1% BSA and Blotto as blocking buffer and sample diluents was observed; on the other 
hand, a dramatically increased sensitivity of ELISA was found while comparing changes of 
coating temperature and serial dilution of antibodies.  
The best result of Enzyme-linked immunosorbent assay (ELISA) can be yielded by 
coating 96-well polystyrene microplates with purified p20 (400ng per well) overnight at room 
temperature and incubating with clinical sera (1:30 dilution) from Inflammatory bowel disease 
(Crohn’s disease, Ulcerative Colitis), non IBD patients and healthy individual controls for two 
and half hours followed by an anti-human IgG secondary antibody conjugated to horseradish 
peroxidase (1:6000 dilution) for one hour at room temperature. Blotto reagent containing 10% 
non-fat milk in PBS buffer and Tween-20 at final concentration of 0.05% was used to block the 
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empty space before adding clinical sera and multiple washes with PBST between each step in 
order to reduce background and yield higher assay sensitivity and specificity. Anti-XpressTM 
antibody (1:1000 dilution) and Rabbit sera (1:250 dilution) provided from Baylor College, Texus 
were included into each batch as positive control, whereas the PBS served as negative control. 
 
Use of ELISA to Measure MAP Infection in Clinical Sera 
A total of 217 subjects including 134 Crohn’s disease, 10 ulcerative colitis and 61 non-
Inflammatory bowel disease and healthy control were tested against purified heterologous 
expressed MAP protein (p20). The net absorbance (OD450 ) for each sample was listed in Table 
2A-D and shown in Figure 14 and the cut off value was established as 0.3. Accordingly, The 
seropositivity rates for each group are as follows: 116 of 134 CD (87%) sera reacted with p20, 
while only 8 of 22 UC (36%) and 16 of 61(26%) non-IBD and healthy controls sera showed 
seropositive with recombinant protein p20 respectively. 
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Figure 11: Evaluation of Purified Recombinant Protein (p20) Immunoreactivity against Clinical 
Sera. Purified protein was loaded on a 12% SDS-PAGE gel and blotted onto a nitrocellulose 
membrane. The membrane strips were screened against Anti-XpressTM antibody, clinical sera 
from patients with crohn’s disease and healthy controls. Lanes:   protein size standards as in 
dicated; 1,17: anti-XpressTM antibody; 2-6: normal healthy control; 7-16: CD sera. 
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Figure 12: Optimization of Enzyme linked Immunosorbent Assay (ELISA). (A) The blocking 
effect of 1% BSA (green) and Blotto reagent (yellow). No significant difference was observed; 
however, utilization of BSA seems yield slightly higher background than Blotto solution. 1: 
Blocking (+), anti-XpressTM antibody (-); 2: Blocking (+), anti-XpressTM antibody (+); 3: 
Blocking (-), anti-XpressTM antibody (+); 4: without blocking and conjugates. (B) Optimal 
dilution of anti-XpressTM antibody as conjugate. The reactivity of serial dilution from 1 to 250 to 
1 to 1000 against p20 was investigated. 1: blocking (-), Ab (1:4000); 2: without blocking and 
conjugates; 3, 4, 5: blocking (+) with Ab (1to 250, 1 to 1000, 1 to 4000 respectively). 
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Figure 13: Optimization of Enzyme linked Immunosorbent Assay (ELISA). (A) The effect of 
binding capacity of recombinant protein (p20) to polystyrene microplates under different coating 
temperature. Purified p20 was incubated at either 4°C(blue) or Room temperature (RT, purple) 
overnight before blocking step. Assay was then performed in parallel with anti-XpressTM 
antibody (positive control), PBS buffer alone (negative control) and serial dilution of CD sera 
from 1to 30 to 1 to 30,000. The best result can be obtained while coating protein at RT and using 
1 to 30 as dilution factor for CD sera.  1: anti-XpressTM antibody; 2, PBS buffer alone; 3-6: serial 
dilution CD sera (1to30, 1to 300, 1 to 3000, 1 to 30000 respectively). (B) Seroreactivity of serial 
dilution of rabbit sera which was either preimmunized with MAP (R2B6-Pink) or not (Rabbit N-
Blue). 1-8 represent 0, 1 to 125, 1 to 250, 1to 500, 1 to 1000, 1 to 2000, 1to 4000 and 1 to 8000, 
respectively. 
64 
 
  
 
A. 
0
0.5
1
1.5
2
A
bs
or
ba
nc
e 
(O
D
 45
0)
1 2 3 4 5 6
Serum dilution
4∘C
RT
 
B. 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
1 2 3 4 5 6 7 8
Rabbit Serum Dilution
A
bs
or
ba
nc
e 
(O
D
 45
0)
Rabbit N
Rabbit R2B6
 
 
 
 
65 
 
  
 
Table 2: Measurement of anti-MAP IgG in Clinical Sera from IBD patients 1-217 
Code Diagnosis Net Code Diagnosis Net
1 CD 0.1060 37 CD 0.7045
2 CD -0.0050 38 CD 0.6375
3 CD 0.3975 39 CD 0.6380
4 CD 0.2960 40 CD 0.3785
5 CD 1.5700 41 CD 0.5085
6 CD 1.7045 42 CD 0.0150
7 CD 0.2645 43 CD 0.5085
8 CD 1.3165 44 CD 1.6455
9 CD 1.8030 45 CD 0.4670
10 CD 0.9260 46 CD 0.5850
11 CD 0.6450 47 CD 0.4500
12 CD 0.5830 48 CD 0.7015
13 CD 0.3215 49 CD 0.6985
14 CD 0.2310 50 CD 0.9680
15 CD 0.3595 51 CD 0.5335
16 CD 1.5770 52 CD 0.7025
17 CD 0.4170 53 CD 0.5580
18 CD 1.7530 54 CD 0.9120
19 CD 1.7710 55 CD 1.6810
20 CD 1.1070 56 CD 1.6155
21 CD 0.5420 57 CD 0.7725
22 CD 0.7100 58 CD 1.4330
23 CD 0.3510 59 CD 1.7165
24 CD 0.7250 60 CD 1.7020
25 CD 0.6310 61 CD 0.2560
26 CD 0.5985 62 CD 0.4115
27 CD 0.7185 63 CD 0.3525
28 CD 0.6495 64 CD 0.2305
29 CD 0.7120 65 CD 0.0645
30 CD 0.5900 66 CD 0.3045
31 CD 1.5860 67 CD 0.2735
32 CD 0.3980 68 CD 0.4565
33 CD 0.4430 69 CD 1.0560
34 CD 0.5225 70 CD 1.0705
35 CD 0.4980 71 CD 1.1695
36 CD 0.6025 72 CD 1.1430  
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Code Diagnosis Net Code Diagnosis Net
73 CD 0.7940 110 CD 1.4755
74 CD 1.0680 111 CD 0.1840
75 CD 0.0630 112 CD 1.5310
76 CD 0.1663 113 CD 1.8205
77 CD 0.0941 114 CD 1.6505
78 CD 0.1388 115 CD 0.2695
79 CD 0.6420 116 CD 0.3065
80 CD 1.5100 117 CD 0.3175
81 CD 0.7610 118 CD 0.7310
82 CD 0.0465 119 CD 0.2335
83 CD 0.4550 120 CD 0.3630
84 CD 1.6840 121 CD 1.6555
85 CD 0.3170 122 CD 1.3805
86 CD 1.3930 123 CD 0.3810
87 CD 1.2020 124 CD 0.4795
88 CD 1.3815 125 CD 1.5890
89 CD 0.8895 126 CD 1.7865
90 CD 0.3865 127 CD 0.9120
91 CD 1.7110 128 CD 1.5610
92 CD 1.0715 129 CD 1.3795
93 CD 0.8875 130 CD 1.5480
94 CD 1.2555 131 CD 0.0150
95 CD 0.9235 132 CD 1.6950
96 CD 1.4230 133 CD 0.6985
97 CD 0.2260 134 CD 0.7405
98 CD 0.2290 135 UC 0.0240
99 CD 1.6760 136 UC 0.0430
100 CD 1.1920 137 UC 0.0500
101 CD 1.4755 138 UC 0.4735
102 CD 0.2410 139 UC 0.2530
103 CD 0.3490 140 UC 0.7670
104 CD 0.1460 141 UC 0.2730
105 CD 1.1850 142 UC -0.0635
106 CD 0.1485 143 UC -0.1710
107 CD 0.4465 144 UC 0.3915
108 CD 0.4235 145 UC 0.6185
109 CD 1.6735 146 UC 0.7755
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Code Diagnosis Net Code Diagnosis Net
147 UC 0.2470 184 Control 0.0950
148 UC 0.2990 185 Control 0.0755
149 UC 0.2580 186 Control 0.0175
150 UC 0.7765 187 Control 0.0000
151 UC 0.2650 188 Control 0.2475
152 UC 0.5085 189 Control 0.2450
153 UC 0.2730 190 Control 0.0845
154 UC 0.3840 191 Control 0.0570
155 UC 0.2975 192 Control 0.0585
156 UC 0.2450 193 Control 0.0845
157 Control 0.4720 194 Control 0.0230
158 Control 0.0935 195 Control 0.0410
159 Control 0.0945 196 Control 0.0280
160 Control 0.3370 197 Control 0.0230
161 Control 0.2580 198 Control 0.0470
162 Control 0.7540 199 Control 0.0305
163 Control 0.0385 200 Control 0.4095
164 Control 0.3490 201 Control 0.4000
165 Control 0.0010 202 Control 0.5950
166 Control 0.0355 203 Control 0.1680
167 Control 0.0835 204 Control 0.0830
168 Control 0.0750 205 Control 0.0430
169 Control 0.0155 206 Control 0.0905
170 Control 0.0125 207 Control 0.1040
171 Control 0.0270 208 Control 0.1490
172 Control 0.3860 209 Control 1.0720
173 Control 0.5510 210 Control 0.1850
174 Control 0.3525 211 Control 0.0390
175 Control 0.1520 212 Control 0.1075
176 Control 0.6865 213 Control 0.5325
177 Control 0.5680 214 Control 0.4695
178 Control 0.4205 215 Control 0.0490
179 Control -0.0070 216 Control 0.0200
180 Control 0.1485 217 Control* 0.0575
181 Control 0.2395
182 Control 0.2645
183 Control 0.0785  
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Figure 14: Seroactivities of the p20 against Sera of Patients with CD, UC or NIBD. Assay was 
conducted by coating P20 antigen (400ng) per well and then incubating with sera of patients with 
CD, UC or NIBD and healthy individuals followed by adding anti-human IgG conjugated with 
HRP (1:6000). A: CD sera; B: UC sera; C: NIBD and controls. 
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Figure 15: Seropositivity Rates for CD, UC or NIBD and Healthy Controls Groups. (A)While cut 
off value was established as 0.3, the positive rate for each group was determined as 87%, 36 % 
and 26% (B) seropositivity rates for IBD and NIBD group. 
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Subcloning of pB11 
Although most of protein from crude cell lysate were removed using Ni-TED prepacked 
affinity columns, small amount of non-specific protein containing some histidine residues on 
their surface would bind to column and be eluted out as tagged protein as well. Those non-
specific proteins in the elution fractions may contribute to false positive in the assay because the 
pB11 insert contains not only the ORF of expressed protein but also additional nucleotide 
sequence that may produce additional peptides. This motivated us to subclone pB11 to minimize 
presence of other encoding sequence. pBAD/His A, B and C vector DNA were digested with 
EcoRI and Hind III restriction endonuclease and analyzed on 1% agarose gel  to ensure complete 
digestion. Double digested vectors were further dephosphorylated by Shrimp alkaline 
phosphatase to prevent self ligation. The efficiency of the dephosphorylation were determined by 
ligating dephosphorylated vectors alone with sterile Millipore water in the presence of T4 DNA 
ligase and transformed into E. coli strain Top 10 competent cells.  The efficiency of 
dephosphorylation was considered satisfactory because no colony was observed on the LB-
ampicillin agar plates. 
Two sets of primers mentioned in the Methodology section were designed in order to 
amplify the predicted open reading frame region from pB11 in pcDNA II plasmid and MAP 
genomic DNA. Initially, the plasmid extraction (pB11 in pcDNAII) was done and analyzed on 
the 1% agarose gel to ensure quantity and purity. A polymerase chain reaction was set by using 
oligonucleotide primers specific to target sequence of the extracted plasmid DNA (pB11 in 
pcDNAII). A single 660 base-pair amplified DNA fragment on 1% agarose gel was detected, 
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whereas no band was observed in the control without templates (shown in Figure 16). Amplified 
DNA fragment was then purified, digested with EcoRI and HindIII restriction endonuclease, and 
further purified to expose both overhang ends without any interference from the templates, 
oligonucleotides, and high salt buffer. Consequently, the ligation reaction was done by using 50 
ng each version (A, B, or C) of dephosphorylated pBAD/His vectors and 25.6ng of digested PCR 
amplified products in the presence of T4 DNA ligase. After electroporation, all the transformants 
were poured and selected on the LB agar plates containing 50 ug/ml ampicillin. Transformation 
efficiency of pBAD/His B and C sets was much lower than that of pBAD/His A. Only 12 
colonies from pBAD/His B and 4 from pBAD/His C grew on the agar plates. 
In addition, another polymerase chain rection was conducted to amplify a 900 bp region 
which was assumed to contain the potential entire ORF region directly from purified MAP Linda 
strain genomic DNA. The assay was done in parallel with PCR reaction cocktails alone (negative 
control) and genomic DNA from E. coli, other strains of MAP and other mycobacteria including 
M. tuberculosis and M. smegamatis. Gel electrophoresis (as Figure 17) showed the presence of 
one band of expected size (900bp) only in Map not in other mycobacteria or E. coli, indicating 
the uniqueness of nucleotide sequence of pB11. Amplified DNA fragments was further digested 
with Kpn I and Hind III, purified, ligated with dephosphorylated pBAD/His expressing vectors, 
and transformed into E.coli Top 10 strain. Transformed cells were first selected on LB plates 
containing 50ug/ml ampicillin as Figure 18 shown. 
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Figure 16: PCR Analysis of Possible ORF Region. Polymerase chain Reactions was performed 
using primers to amplify potential Open Reading Frame Region (ORF) from pB11 in pcDNA II 
(A) and then analyzed on 1% agarose gel. Shown in panel A are DNA size standards (M), 
undigested purified template plasmid DNA (pB11 in pcDNAII, lane 1) and EcoRI digest (pB11 
in pcDNAII). Panel B represents DNA size standards (M), amplified products (lane 1) and 
reagent mixture negative control (lane 2). The amplified necleotide sequence is listed in panel C. 
Primer annealing sites are marked underline, whereas the stop codon as green and two restriction 
endonuclease recognition sites as red.  
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GTGGCGGAATTGTAATACGACTCACTATAGGGCGAATTGGGCCCTCTAGATGCATGCTCGAG
CGGCCGCCAGTGTGATGGATATCTGCAGAATTCTCGCGACGGTGGCGATGTCGTCGTCGGCG
GTGCGCCGCGGCAGCAGCGCCAGCGTCGGCGCGTAGCCGACGGCGGGCGCCTGCCGGGGAT
AGCCCGCGCGCAAAAACCCGACCACGCCGCCCACCAGCTGCCCCAGGCCCATGTCTCACCTC
GCTACCTCACCGCACGCCGCACGCCGACAACGCCGTTGCACCCCGAATAGCCGGACCCGATC
GGTTGAAACCCACGCGCACGGAAAGGGCCCGGTCCGCCGATCGGACCGGGCCCCTCCCCTT
GGCGGGCAGCCTATTGGTTCTTCTTCTGGCGCTCCTCGGCGGCCTCCGCGCCGGCCCGCGCC
GACTCGGCCTCGGCTTCCTTCTTGCCCGCGTCGCGCTGGGCGTCGGCCTTGTCCTGCTGGGCC
TGACCCTCTTCGGTCAGGTCGTCGCGGCCGAGGATGGTCCCGCCGACCTCCTTGGCCTTGCC
CTTCACGCCCTCGACGGCGCCTTTGACCGCTTCCTGCGGCCCGCTCTGCTGGTCCCCCATGGG
TTCGACCTCTCTGGTAGGTGGTGAGTGAGCAAGCTTCGCT 
  
 
  
 
 
 
 
 
 
Figure 17: PCR Analysis of Possible ORF Region. Polymerase chain Reactions was performed 
using primers to amplified potential Open Reading Frame Region (ORF) directly from genomic 
DNA of MAP. PCR products were analyzed on 1% agarose gel; a single band at 900 bp was 
observed when use two strains of MAP as templates but no product was found in the other 
mycobacteria and E.coli, representing the uniqueness of amplified fragment. Lanes: M: DNA 
size standards; 1: MAP Linda strain; 2: st6; 3: M.tuberculosis. 4: M.smegmatis; 5: E.coli Top 10 
strain. 
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Figure 18: Colonies Morphology of Possible pB11 Subclone. The purified PCR amplified 
products were ligated with different version of  cloning system (pBAD/His), electroporated into 
E.coli Top 10 strain and selected on LB agar plates containing 50 ug/ml ampicillin (A,B,C). 
Panel D represents negative control (Top 10 cells alone was electroporated then plated on the 
agar plates.) 
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Colonies from each set were picked up for Cell pop PCR to confirm the presence of insert 
of interest. In this assay, colonies directly served as template DNA without an extra step of 
plasmid extraction and two oligonucleotides specific to insert sequence were used to amplify 817 
base pair region. In the trial of pB11 subclone, 9 out of 10 from pBAD/His A, all of 12 from 
pBAD/His B, and 1 out of 4 from pBAD/His C  showed a positive clear 817 bp amplified 
product on 1 % agarose gel as Figure 19B shown. 
 On the other hand, in the trial of amplifying entire possible ORF, all colonies   were Cell 
pop PCR positive for the presence and orientation of insert as shown in Figure 19   panel C. One 
positive recombinant from pBAD/His B in the trial of pB11 subclone, designated as pB11/B6 
was grown and expressed protein under 2% L- Arabinose induction. The expression of 
recombinant protein was then analyzed on 12% SDS-PAGE gel followed by immunoblotting. As 
the Figure 20 shown, recombinant protein (p20) was successfully expressed in subclone 
pB11/B6 even though the protein yield appeared differently when compared with pB11. 
Moreover, the seroactivity of purified fusion protein from pB11, pB11/B6 and pBAD/His B 
vector only against human sera was investigated. The immunoblot strips containing purified 
recombinant protein (p20) and tag portion only were tested against anti-XpressTM antibody and 
sera from CD patients and healthy individuals. Whereas CD patient sera appeared positive with 
either purified pB11and pB11/B6 but not with purified tag protein, normal healthy control 
reacted none of them as expected. 
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Figure 19: Cell Pop PCR Detection of Possible pB11 Subclones.  Transformants were randomly 
picked as templates without plasmid extraction and further screened to ensure the presence and 
orientation of insert by using the primers to amplified possible ORF region.  Panel A: 
thermalcycler programming; panel B and C: M: DNA size standards; 1-15 represents individual 
colony randomly picked from the plates. 
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Figure 20: Immunoblotting Analysis of Cell-Pop PCR Positive Transformants. Cell pop PCR 
positive clone was grown and induced. Cell lysates were separated on 12% SDS-PAGE gel and 
blotted on to nitrocellulose. Anti-XpressTM    and Anti-His  TM antibodies were used to detect the 
presence of fusion protein. M: protein size standards. 1, 4: pBAD/His B; 2, 5: pB11, 3, 6: 
pB11/B6. 
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Figure 21: Evaluation of Seroactivity of Purified Recombinant Protein p20 against Human Sera.  
Recombinant protein and tag protein were purified from pB11 (A), pB11/B5 (B) and pBAD/His 
B (C) vector using Ni-TED purification column. Immunoblot strips containing these proteins 
were incubated with sera from CD (A, lane 2 and B lane 3), healthy individual (A, lane 1, B, C: 
lane 2) and anti-XpressTM antibody (A, lane3, B, lane 1). 
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CHAPTER FOUR: DISCUSSION AND CONCLUSION 
The incidence and prevalence of CD has dramatically increased during the last 50 years; 
however, the etiology and mechanism of this disorder to date still remain unveiled. Besides 
genetic susceptibility, researchers have intensely investigated the role of environmental triggers 
such as smoking, the measles virus, mycobacteria and the commensal micro flora normally 
reside in the gut, which breaks down the homeostasis and lead to dysregulated immune responses. 
Out of proposed possible causative agents, the association between MAP and CD has drawn a lot 
of attention because of the clinical resemblance to Johne’s disease (granulomatous disease in 
ruminants), the capability of isolating MAP from tissue specimen of CD patients and pasteurized 
milk and the remission elicited by administration of anti-mycobacterial drugs. 
Currently, the diagnosis of CD depends on the combination of clinical manifestations, 
radiographic, endoscopic and histological findings. However, the overlapping non-specific 
symptoms usually lead to misinterpretation and misdiagnosis. In addition, even though barium 
contrast X-ray and endoscopy have become routine diagnostic tools, discomfort, high cost, and 
the invasive and time consuming  nature of these procedures discount their applications. Other 
than these expensive imaging techniques, several serodiagnostic tools such as lactoferrin 
detection kit, and autoantibodies monitors have been tested so far, but the low sensitivity and the 
cross reactivity of antigens used in these assays made the diagnosis process more difficult and 
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complicated, thereby limiting their usefulness. The need for a specific, sensitive, noninvasive and 
rapid assay to assist physicians to make differential diagnosis easier and monitor disease activity 
motivated us to develop an immunoassay specific for MAP antigens. A genomic library of MAP 
Linda strain was constructed into E. coli using pBAD/His cloning vectors two years ago. The 
recombinant protein (p20) from clone pB11 consists of 1088 bp with an open reading frame of 
549 bp was found to react with most sera of patients with CD but not with those of UC or healthy 
individuals, implying the immunogenecity of this recombinant protein and its potential use as a 
serologic diagnostic marker.  
In this study, a highly specific, sensitive enzyme linked immunosorbent assay (ELISA) 
was developed. Recombinant protein (p20) was overexpressed and successfully purified under 
native condition using immobilized metal chelating affinity chromatography (IMAC). The 
seroreactivity of purified recombinant protein (p20) against clinical sera was evaluated in 
immunoblotting studies and showed positive for CD sera but not for others, which was consistent 
to previous studies in our lab. Purified protein as an antigen was further quantified and coated to 
96 well microplates under optimal condition. A total of 217 sera samples including 134 Crohn’s 
disease (CD), 22 Ulcerative Colitis (UC) and 61 non-IBD or healthy individuals were tested. 
Whereas 116 out of 134 CD (87%) serum samples was positive to the recombinant protein (p20), 
only 8 of 22 UC (36%) and 16 of 61 non IBD and healthy controls (26%) appeared positive 
when cut off value was established as 0.3.  
To prevent a false positive result in the ELISA, probably from the extra encoding 
sequence outside the open reading frame, a subclone of pB11, designated as pB11/B6, was 
constructed. Nucleotide sequences representing the predicted coding region were amplified and 
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cloned back into the E. coli expression vector, pBAD/His. Immunoblotting analysis showed that 
new clone still produces fusion protein at expected size (20kDa) even though the protein yield 
was different from its source, pB11. Overexpression strategies and Seroreactivity of recombinant 
protein (p20) from pB11/B6 subclone still needs to be investigated before being used in ELISA.  
In conclusion, the recombinant protein (p20) was proven a candidate for diagnostic 
serological marker for diagnosis of inflammatory bowel disease. Development of a faster, non-
invasive, much cheaper, highly specific and sensitive immunoassay such as ELISA is attainable 
and promising. Still, more clinical sera from other diseases such as opportunistic infection with 
M. avium or any other mycobacteria species, ulcerative Colitis and healthy controls need to be 
included to establish a better cut-off value. This molecular diagnostic test could also serve as a 
good screening tool for population based epidemiological studies such as geographic distribution, 
age and ethnic group in order to gain much clearer picture about the etiopathological mechanism 
of CD, which might be helpful for disease prevention and controls in the future. 
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